Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

multidrug resistant infections

EISAI

Eisai’s thyroid cancer drug Lenvima nears EU approval

Positive recommendation by the CHMP could see the orphan drug used in Europe within three months

UK Life Sciences Strategy - one year on

AstraZeneca joins Genomics England consortium

Combines with other pharma firms such as Illumina to utilise genetic data to create new medicines

- PMLiVE

AZ links with Harvard for diabetes research

Firm extends ties with the highly respected academic institution in hope of finding innovative leads

- PMLiVE

AZ and Daiichi Sankyo sign Movantik marketing deal

Two firms have agreed the deal for the new constipation pill

- PMLiVE

Actavis completes $70.5bn Allergan acquisition

Finalisation comes after bidding war with deal-hungry Valeant

- PMLiVE

AstraZeneca scores in final lung disease drug trials

The firm hopes it LAMA/LABA drug can take a big chunk from the $14bn COPD market

- PMLiVE

AstraZeneca’s heart drug impresses, but bleeding risks a concern

Firm still hopes the new Brilinta data can help the medicine be a blockbuster

- PMLiVE

AstraZeneca bullish on diabetes franchise fortunes

Other big pharma firms face a difficult 2015, but AZ is confident it won't

- PMLiVE

Actavis gets FDA nod for new antibiotic

Avycaz is the fifth antibiotic to gain US approval in recent months

- PMLiVE

NICE recommends Ozurdex for diabetic eye condition

Draft guidance cites implant as option for patients with diabetic macular oedema

- PMLiVE

AZ gets injunction to protect Pulmicort Respules

Actavis blocked from selling generic five days after AZ’s asthma launch

- PMLiVE

AstraZeneca employs Wolfram tech for liver health research

Project could produce mathematical models that can detect liver problems

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links